Analyzing Endonovo Therapeutics (OTCMKTS:ENDV) and Sana Biotechnology (NASDAQ:SANA)

Endonovo Therapeutics (OTCMKTS:ENDV) and Sana Biotechnology (NASDAQ:SANA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, profitability, risk, dividends, earnings and analyst recommendations.

Volatility and Risk

Endonovo Therapeutics has a beta of -1.03, suggesting that its share price is 203% less volatile than the S&P 500. Comparatively, Sana Biotechnology has a beta of 2.16, suggesting that its share price is 116% more volatile than the S&P 500.

Profitability

This table compares Endonovo Therapeutics and Sana Biotechnology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Endonovo Therapeutics	N/A	N/A	N/A
Sana Biotechnology	N/A	-102.39%	-39.71%

Earnings & Valuation

This table compares Endonovo Therapeutics and Sana Biotechnology”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Endonovo Therapeutics	$10,000.00	14.46	-$2.18 million	N/A	N/A
Sana Biotechnology	N/A	N/A	-$244.17 million	($0.76)	-5.01

Endonovo Therapeutics has higher revenue and earnings than Sana Biotechnology.

Institutional & Insider Ownership

88.2% of Sana Biotechnology shares are held by institutional investors. 5.6% of Endonovo Therapeutics shares are held by company insiders. Comparatively, 25.4% of Sana Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and price targets for Endonovo Therapeutics and Sana Biotechnology, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Endonovo Therapeutics	0	0	0	0	0.00
Sana Biotechnology	1	1	7	0	2.67

Sana Biotechnology has a consensus target price of $9.50, suggesting a potential upside of 149.34%. Given Sana Biotechnology’s stronger consensus rating and higher possible upside, analysts plainly believe Sana Biotechnology is more favorable than Endonovo Therapeutics.

Summary

Sana Biotechnology beats Endonovo Therapeutics on 6 of the 10 factors compared between the two stocks.

About Endonovo Therapeutics

Endonovo Therapeutics, Inc., a biotechnology company, develops, manufactures, and distributes non-invasive Electroceutical medical devices for regenerative medicine. The company offers SofPulse, a non-invasive Electroceutical therapeutic device for the palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain and edema. Its Electroceuticals medical device is also used for the treatment of cardiovascular diseases, chronic kidney, liver diseases, non-alcoholic steatohepatitis, cardiovascular and peripheral artery diseases, and ischemic stroke, as well as for central nervous system disorders, such as traumatic brain injury, acute concussions, post-concussion syndrome, stroke, and multiple sclerosis. Endonovo Therapeutics, Inc. was founded in 2008 and is based in Woodland Hills, California.

About Sana Biotechnology

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company’s product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin’s lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam’s proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.